Beclomethasone Dipropionate + Formoterol Fumarate

Ascon-F is indicated for the treatment of asthma and COPD.
Asthma
: This inhaler is indicated in the regular treatment of asthma where use of a combination of inhaled corticosteroid and long-acting P2 adrenergic agonist is appropriate.
COPD
: This inhaler is indicated for the symptomatic treatment of severe COPD and a history of repeated exacerbations despite regular therapy with long acting bronchodilators.

Common side effects
: Adverse events which have been associated with Beclomethasone and Formoterol are
hypokalemia, headache, tremor, palpitations, cough, muscle spasms and prolongation of QTs interval.
Rear Side Effects
: Rash, Urticaria pruritus, erhythema and oedema of the eyes, face,lips & throat may also occur.

This preparation is a combination of Beclomethasone Dipropionate BP and Formoterol Fumarate Dihydrate BP. It is a hydrofluoroalkane (HFA) based environment friendly inhaler. Because it does not contain chlorofluorocarbon (CFC) as propellant which is one of the main reasons of ozone layer depletion. Beclomethasone Dipropionate is a synthetic halogenated corticosteroid with potent anti-inflammatory activity. It given by inhalation has a potent glucocorticoid anti-inflammatory action within the lungs without the side effects observed when steroids are administered systemically. Formoterol Fumarate Dihydrate is a long acting selective P2 adrenergic agonist with a rapid onset of action. Inhaled Formoterol acts in the lung as a bronchodilator.When used as an inhaler, the medication goes directly into the lungs and very little finds its way into the rest of the body.